Lonza Group is a Swiss contract development and manufacturing company that serves pharmaceutical, biotech and specialty ingredient customers. It makes active pharmaceutical ingredients, biologics and cell and gene therapy products for drug developers, and supplies microbial control and hygiene ingredients for consumer and industrial markets. The company is based in Basel, Switzerland, and works with healthcare and life-science customers around the world through its manufacturing and development services.
Lonza Group AG trades under the code 0QNO on the London Exchange in UK, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
The first paragraph was written with AI from general knowledge about the company and checked automatically; the second comes from our own data. It can contain mistakes: check the company's own website and filings before relying on it.
Market X-Ray · price-based
Strong price profile
Ranks #330 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
84/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average14.7%
From 52-week high0.0%
MomentumFair
69/100
Typical recent returns for this exchange.
See the numbers →
3-month return14.1%
6-month return19.9%
12-month, skipping last month0.0%
Risk (lower is better)Strong
75/100
Calmer than most: low volatility and shallow drawdowns.
See the numbers →
Volatility (1 year)23.9%
Worst drawdown (1 year)-20.2%
LiquidityStrong
82/100
Trades actively.
See the numbers →
Avg daily value traded32.14M CHF
Zero-volume days0.0%
IncomeWeak
40/100
Dividend is small or irregular.
See the numbers →
Dividend yield0.4%
Years with dividends5
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 452.76 – 613.00Daily closes, split-adjusted
Signals
50-day average570.76
200-day average533.26
Golden/death cross (60d)None
New 52-week highYes
Bullish RSI divergenceNo
Average daily range (ATR)13.47
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10
584.8
Bullish
EMA 10
588.4
Bullish
SMA 20
577.6
Bullish
EMA 20
579.5
Bullish
SMA 50
570.8
Bullish
EMA 50
569.6
Bullish
SMA 100
556.1
Bullish
EMA 100
557.5
Bullish
SMA 200
533.3
Bullish
EMA 200
546.0
Bullish
Oscillators (daily)
RSI (14)
66.35
Neutral
MACD (12, 26)
9.27
Bullish
Momentum (12)
9.06
Bullish
Stochastic %K (14)
97.93
Bearish
Williams %R (14)
-2.07
Bearish
CCI (20)
201.7
Bearish
Pivot points (classic, last session)
S3
587.2
S2
592.6
S1
602.2
Pivot
607.6
R1
617.2
R2
622.6
R3
632.2
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.50 CHF
Yield on today's price
0.41%
Frequency
Annual
Next ex-dividend date
Not announced
Ex-dividend date
Amount per share
12 May 2026
2.5000
13 May 2025
2.0000
13 May 2024
2.0000
9 May 2023
1.7500
9 May 2022
1.5000
10 May 2021
1.5000
30 Apr 2020
1.3750
24 Apr 2019
2.7500
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
Prices are end-of-day closes in CHF. Educational only, not financial advice.